Recent, a study using MCC950, a selective NLRP3 inhibitor, demonstrated significant reductions in IL-1β production and partial recovery in synaptic function, pointing to the potential of inflammasome-targeted treatments to counteract AD’s inflammatory component [133]. This evidence concerns the gene NLRP3 and Alzheimer disease.